CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma
-
By
-
Yiming Yang
-
Biyang Zeng
-
Huimin Yang
-
Xin Liu
-
Peilin Li
-
Chao Mai
-
Shunhai Jian
-
Qiqi Zhu
-
July 7, 2026
-
Clinical Scorecard: Elevated CD244 Levels Correlate with Natural Killer Cell Impairment and Tumor Advancement in Diffuse Large B-Cell Lymphoma
At a Glance
| Category | Detail |
|---|
| Condition | Diffuse Large B-Cell Lymphoma (DLBCL) |
| Key Mechanisms | CD244 expression in NK cells correlates with immune dysfunction and tumor progression. |
| Target Population | Patients diagnosed with DLBCL. |
| Care Setting | Oncology and Hematology |
Key Highlights
- CD244 is associated with NK cell dysfunction and adverse clinical outcomes in DLBCL.
- Elevated CD244 levels correlate with an immunosuppressive tumor microenvironment.
- CD244 may serve as a potential therapeutic target for optimizing immunotherapy.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of DLBCL should follow the World Health Organization criteria.
Management
- Standard therapy includes R-CHOP regimen.
Monitoring & Follow-up
- Monitor CD244 levels as a potential prognostic marker.
Risks
- Elevated CD244 levels may indicate poorer prognosis and treatment resistance.
Patient & Prescribing Data
153 DLBCL cases diagnosed prior to chemotherapy.
Patients with elevated CD244 may have increased susceptibility to immune checkpoint blockade therapy.
Clinical Best Practices
- Integrate CD244 expression analysis in the assessment of DLBCL.
- Consider targeting CD244 in immunotherapy strategies for DLBCL.
Related Resources & Content
